20348-23-6

Basic information

• Product Name: 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine
• Synonyms: 3,4-DIHYDRO-2H-PYRIDO[3,2-B][1,4]OXAZINE;3,4-Dihydro-2H-pyrido[3,2-b]oxazine;2H,3H,4H-pyrido[3,2-b][1,4]oxazine;2,3-dihydropyrido[3,2-b][1,4]oxazine
• CAS NO: 20348-23-6
• Molecular Formula: C₇H₈N₂O
• Molecular Weight: 136.15122
• Product Categories: Heterocyclic Series
• Mol File: 20348-23-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 85 °C
• Boiling Point: 285.731 °C at 760 mmHg
• Flash Point: 126.606 °C
• Appearance: /
• Density: 1.168
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.82±0.20(Predicted)
• CAS DataBase Reference: 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine(20348-23-6)
• EPA Substance Registry System: 3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine(20348-23-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 20348-23-6(Hazardous Substances Data)

Usage

General Description

3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazine, also known as dioxazine, is a heterocyclic compound with a molecular formula C9H9NO. It is a colorless, crystalline substance that is used as a precursor and intermediate in the production of various dyes and pigments, such as solvent violet 8 and insoluble pigments. Dioxazine is also used in the manufacturing of pharmaceuticals, polymers, and other organic compounds. It is a versatile and important chemical in the industry, with a wide range of applications due to its unique structure and properties.

InChI:InChI=1/C7H8N2O/c1-2-6-7(8-3-1)9-4-5-10-6/h1-3H,4-5H2,(H,8,9)

Upstream product

• 20348-09-8 4H-pyrido[3,2-b][1,4]oxazin-3-one 
• 959992-62-2 6-bromo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]oxazine 
• 149-73-5 trimethyl orthoformate 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 34950-82-8 7-bromo-3,4-dihydro-2H-pyrido[3,2-β][1,4]oxazine 

Relevant articles and documents

RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

CYCLOPROPYL MIDA BORONATE

This disclosure concerns a protected cyclopropylboronic acid comprising a substituted cyclopropyl group and a boronic ester group having a protecting group. The protecting group is an N-methyliminodiacetic acid (MIDA) group or MIDA-based group.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.